In a study that tested the combined administration of halofuginone and gemcitabine in pancreatic cancer, halofuginone administration sensitized KPC mouse-derived pancreatic cancer cell lines to gemcitabine in vitro and in vivo, along with reduction of aldehyde dehydrogenase 3a1 (Aldh3a1) [99]. Here, ALDH3A1 is linked to familial pancreatic carcinoma.